Oral combination therapy: Repaglinide plus metformin for treatment of type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 10, Issue 12, 2008, Pages 1167-1177

  Raskin, Philip ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Fixed combination treatment; Metformin; Repaglinide; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DRUG COST; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN SENSITIVITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 55449100048     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00907.x     Document Type: Review

References (97)

1. World Health Organisation. Prevalence of diabetes worldwide, 2006. Available from http://www.whoint/diabetes/facts/world_figures/en/.
2. ACE/AACE Diabetes Road Map Task Force: Road map for the prevention and treatment of type 2 diabetes ACE/AACE Diabetes Recommendations Implementation Conference, 2005.
3. ADA. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007; 30: S4-S41.
4. Summary of revisions for the 2006 Clinical Practice Recommendations. Diabetes Care 2006; 29 (Suppl. 1): S3.
5. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721.
6. McCance DR, Ritchie CM, Kennedy L. Is HbA1 measurement superfluous in NIDDM? Diabetes Care 1988; 11: 512-514.
7. Bastyr EJ III, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000; 23: 1236-1241.
8. Monnier L, Colette C, Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract 2006; 12 (Suppl. 1): 42-46.
9. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
10. AACE. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 (Suppl. 1): 1-68.
11. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 1535-1540.
12. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
13. U.K. Prospective Diabetes Study 16. Overview of 6 years'therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 1249-1258.
14. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
15. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
16. Moses R. Repaglinide in combination therapy with metformin in type 2 diabetes. Exp Clin Endocrinol Diabetes 1999; 107 (Suppl. 4): S136-S139.
17. Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003; 46 (Suppl. 1): M44-M50.
18. Bailey CJ, Day C. Metformin: Its botanical background. Pract Diabet Int 2004; 21: 115-117.
19. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
20. Zang M, Zuccollo A, Hou X, et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 2004; 279: 47898-47905.
21. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074-2081.
22. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24: 489-494.
23. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-2069.
24. Palumbo PJ. Metformin: Effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12: 110-119.
25. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
26. Willms B, Ruge D. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: A randomized, placebo-controlled study. Diabet Med 1999; 16: 755-761.
27. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-124.
28. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005: CD002966.
29. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 2006; 29: 504-509.
30. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
31. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
32. Owens DR. Repaglinide - prandial glucose regulator: A new class of oral antidiabetic drugs. Diabet Med 1998; 15 (Suppl. 4): S28-S36.
33. Campbell IW. Nateglinide - current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract 2005; 59: 1218-1228.
34. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995; 38: 1025-1032.
35. Hu S. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action. Eur J Pharmacol 2002; 442: 163-171.
36. Hansen AM, Hansen JB, Carr RD, Ashcroft FM, Wahl P. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels. Br J Pharmacol 2005; 144: 551-557.
37. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.
38. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002; 41: 471-483.
39. McLeod JF. Clinical pharmacokinetics of nateglinide: A rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004; 43: 97-120.
40. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23: 202-207.
41. Rudovich NN, Leyck Dieken MG, Rochlitz H, Pfeiffer AF. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2004; 112: 395-400.
42. Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes 2002; 51: 2789-2795.
43. Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004; 53 (Suppl. 3): S156-S164.
44. Smits P, Bijlstra PJ, Russel FG, Lutterman JA, Thien T. Cardiovascular effects of sulphonylurea derivatives. Diabetes Res Clin Pract 1996; 31 (Suppl.): S55-S59.
45. Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience. Clin Ther 2003; 25: 799-816.
46. Smedegaard Kristensen J, Brown Frandsen K, Bayer T, Muller PG. Repaglinide treatment is associated with significantly less severe hypoglycemic events compared to sulfonylureas. Diabetologia 1999; 42: A4.
47. Moses R. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin Pharmacother 2000; 1: 1455-1467.
48. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: A solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? Int J Obes Relat Metab Disord 2000; 24 (Suppl. 3): S21-S31.
49. Papa G, Fedele V, Rizzo MR, et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial. Diabetes Care 2006; 29: 1918-1920.
50. Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002; 58: 45-53.
51. Damsbo P, Clauson P, Marbury TC, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999; 22: 789-794.
52. Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001; 24: 983-988.
53. Tankova T, Koev D, Dakovska L, Kirilov G. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract 2003; 59: 43-49.
54. Black C, Donnelly P, McIntyre L, Royle P, Shepherd J, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007: CD004654.
55. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: A one-year comparison trial. Diabetes Res Clin Pract 1999; 43: 155-166.
56. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22: 463-467.
57. Landgraf R, Bilo HJ, Muller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999; 55: 165-171.
58. Feinglos M, Dailey G, Cefalu W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 2005; 68: 167-175.
59. Baron MA. Comparison of repaglinide and nateglinide in combination with metformin: Response to Raskin et al. Diabetes Care 2003; 26: 3361-3362; author reply 3362-3363.
60. Raskin P, Klaff L, McGill J, et al. Efficacy and safety of combination therapy: Repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003; 26: 2063-2068.
61. Van Gaal LF, Van Acker KL, De Leeuw IH. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. Diabetes Res Clin Pract 2001; 53: 141-148.
62. Verges B. The impact of prandial glucose regulation in practice. Diabetes Nutr Metab 2002; 15: 28-32.
63. Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia. Metabolism 2006; 55: 1263-1281.
64. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004; 164: 2090-2095.
65. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet 1999; 354: 617-621.
66. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
67. Soegondo S, Subekti I, Luthariana L. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients. Acta Med Indones 2004; 36: 142-147.
68. Reboussin DM, Goff DC Jr, Lipkin EW, et al. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabet Med 2004; 21: 1082-1089.
69. Shapiro MS, Abrams Z, Lieberman N. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. Isr Med Assoc J 2005; 7: 75-77.
70. Moses R. Repaglinide in combination therapy. Diabetes Nutr Metab 2002; 15: 33-38.
71. Hollingdal M, Sturis J, Gall MA, et al. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diabet Med 2005; 22: 1408-1413.
72. Sturis JET, Due A-L, Carr RD. Combination of repaglinide and metformin results in greater than additive (synergistic) effects on glucose tolerance in obese Zucker (fa/fa) rats. Diabetes Metab 2003; 29: 4S259.
73. Gerich JE. The importance of tight glycemic control. Am J Med 2005; 118: 7S-11S.
74. Horton ES, Foley JE, Shen SG, Baron MA. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2004; 20: 883-889.
75. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
76. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643.
77. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006; 8: 156-163.
78. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3598-3604.
79. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: The EMPIRE Study. Curr Med Res Opin 2005; 21: 2029-2035.
80. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000; 283: 1695-1702.
81. Rosak C, Petzoldt R, Wolf R, Reblin T, Dehmel B, Seidel D. Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. Int J Clin Pract 2005; 59: 1131-1136.
82. Herder C, Martin S, Kempf K, Rose B, Kolb H. The DREAM trial. Lancet 2006; 368: 2049; author reply 2050-2041.
83. Avandia prescribing information, 2007.
84. Pioglitazone HCl prescribing information, 2007.
85. Catalan VS, Couture JA, LeLorier J. Predictors of persistence of use of the novel antidiabetic agent acarbose. Arch Intern Med 2001; 161: 1106-1112.
86. Jinagouda S. Combination therapy in type 2 diabetes: Repaglinide/ metformin vs glyburide/metformin. Diabetes 2001; 50: A439.
87. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007; 120: 713-719.
88. Palmer AJ, Roze S, Lammert M, et al. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Curr Med Res Opin 2004; 20 (Suppl. 1): S41-51.
89. Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2005; 27: 1548-1561.
90. Dailey GE. Glyburide/metformin tablets: A new therapeutic option for the management of Type 2 diabetes. Expert Opin Pharmacother 2003; 4: 1417-1430.
91. Deeks ED, Scott LJ. Pioglitazone/metformin. Drugs 2006; 66: 1863-1877.
92. Ristic S, Collober-Maugeais C, Pecher E, Cressier F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med 2006; 23: 757-762.
93. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. PRESERVE-beta: Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005; 28: 2093-2099.
94. Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: A double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49-56.
95. Phillips P, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-273.
96. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998; 21: 2050-2055.
97. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880.